Acceleron Pharma

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Merck

Merck & Co., Inc. (MRK) Merck to Acquire Acceleron Pharma Conference Call (Transcript)

NEW YORK--(BUSINESS WIRE)--Avoro Capital, a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron”, “XLRN” or the “Company”) together with certain of its affiliates and managed funds (“Avoro,” “we” or "us"), making it one of the Company's most significant shareholders. Avoro today issued the following statement: Despite the fact that Avoro believes that Acceleron's management team

Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Acceleron Pharma Inc. (NASDAQ: XLRN) to Merck & Co., Inc. for $180.00 per share in cash is fair to Acceleron shareholders. Halper Sadeh encourages Acceleron shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whe

Acceleron Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Acceleron Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XLRN

MILWAUKEE, Sept. 30, 2021 /PRNewswire/ -- Ademi LLP is investigating Acceleron (Nasdaq: XLRN), for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.

Shareholder Alert: Ademi LLP investigates whether Acceleron Pharma Inc. has obtained a Fair Price in its transaction with Merck

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs heart.

Merck buying Acceleron Pharma in $11.5B deal

The move will boost Merck's current pipeline with Acceleron's drugs that treat rare diseases.

Merck and Acceleron Pharma Agree a $11.5 Billion Deal. The Shares Are Up.

Putting all the speculations at bay, Merck & Co Inc (NYSE: MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ: XLRN) for $180 per share in cash for an approximate total equity value of $11.5 billion. Related Link:   Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ.

Merck Seals Acceleron Pharma Deal For $180/Share: Highlights

Merck & Co will buy drugmaker Acceleron Pharma Inc for about $11.5 billion, the companies said on Thursday, as the U.S. pharmaceutical giant looks to beef up its portfolio with drugs for rare diseases.

Merck to buy Acceleron for about $11.5 billion in rare disease drugs push

Merck & Co. MRK, +2.41% said Thursday it has agreed to acquire Acceleron Pharma Inc. XLRN, -4.06% in a deal with an equity value of $11.5 billion that was first reported earlier this week by the Wall Street Journal. Merck will pay $180 in cash for each Acceleron share owned, in a deal that's expected to close in the fourth quarter.

Merck confirms to acquire Acceleron in a deal valued at $11.5 billion

KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Acquire Acceleron Pharma Inc.

Merck to Acquire Acceleron Pharma Inc.

Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.

Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion

Acceleron produces a drug to treat pulmonary arterial hypertension and Reblozyl, used against blood-related disorders.

Merck Reportedly Close to Buying Acceleron Pharma

The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing people familiar with the matter. The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don't fall apart, the people said.

Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.

The Wall Street Journal: Merck nears deal for rare-disease-drug maker Acceleron

Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.

Merck nears deal to acquire Acceleron Pharma

Bristol-Myers

Bristol-Myers Squibb Co. ( BMY , Financial) is the odds-on favorite to acquire Acceleron Pharma Inc. ( XLRN , Financial) and the rights to its two promising drugs, reported Bloomberg.

Bristol-Myers Reportedly Most Likely Buyer of Acceleron Pharma

Merck & Co is in advanced talks to acquire drugmaker Acceleron Pharma Inc, the Wall Street Journal reported https://www.wsj.com/articles/merck-nears-deal-to-acquire-acceleron-pharma-11632778405?mod=latest_headlines on Monday, citing people familiar with the matter.

Merck in advanced talks to buy Acceleron Pharma

Shares of Acceleron Pharma Inc. XLRN, +4.89% gained 3.9% in premarket trading on Monday after Bloomberg reported Friday that an unnamed buyer is considering spending $11 billion to buy the company. Acceleron markets one approved therapy, Reblozy, which is used to treat anemia in some people with the blood disorder beta thalassemia.

Acceleron's stock gains 3.9% on acquisition report

Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is potentially in advanced talks for an $11 billion buyout deal. Acceleron stock opened at $136.6 on 20 September and closed at $167.6 on 24 September, almost a jump of 22% during the period.

Acceleron In Advanced $11B Buyout Talks: Bloomberg

Buyout rumors are swirling around this mid-cap biotech company.

Why Acceleron Pharma Stock Jumped This Week

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2021 Results - Earnings Call Transcript

Acceleron (XLRN) reports a wider loss in the second quarter of 2021 on higher costs and lower revenues.

Acceleron (XLRN) Q2 Loss Wider Than Expected, Revenues Miss

Acceleron (XLRN) delivered earnings and revenue surprises of -14.13% and -10.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Acceleron Pharma (XLRN) Reports Q2 Loss, Misses Revenue Estimates

Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 208.82% over the past year to ($1.05), which missed the estimate of ($0.88).

Acceleron Pharma: Q2 Earnings Insights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the second quarter ended June 30, 2021. “We were very pleased to highlight clinical updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept reported at the annual ATS medical meeting and outline our plans for future

News for Acceleron Pharma Stock (XLRN)